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The rapid methacholine challenge test using a pocket turbine spirometer (Micro SpirometerO) and the Spira 
Elektro 2 dosimeter was performed with 230 consecutive patients who had dyspnoea, wheezing or a prolonged 
cough of unknown cause. Patients with previous asthma diagnoses as well as those who had used inhaled 
steroids during the preceding 4 weeks were excluded. Seventy-eight patients (34%) were methacholine positive 
(PD,,FEVi <69OOpg) 47 (60%) of whom had a final diagnosis of American Thoracic Society (ATS) criteria 
fulfilling bronchial asthma. One hundred and fifty-two patients (66%) were methacholine negative (PD,,FEV, 
>69OO,~g), 14 (9%) of whom had bronchial asthma according to clinical evaluation. Increased bronchial 
responsiveness was strongly associated with ATS criteria fulfilling asthma (P<O.OOOl). When PD,,FEV, was used, 
47. (77%) of the asthmatic patients were hyper-responsive (range 40-6900,ug) compared to 31 (18%) of the 
non-asthmatic patients (range 160-69OOpg). When using PD,,FEV,, 51 (84%) of the asthmatic patients (range 
286900,~~g) and 52 (31%) of the non-asthmatic patients (range lOOG6900,~g) were hyper-responsive. The level of 
bronchial responsiveness measured by both PD,,FEV, and PD,,FEV, differed significantly between asthmatic and 
non-asthmatic patients (P<O,OOOl). 
Hyper-responsiveness was associated with an increased daily variation in peak expiratory flow (PEF) (P<O.OOOl) 
and an increased number of blood eosinophils (P<O.OOOl). Hyper-responsiveness was also associated with decreased 
levels of FEV, and percentages of predicted FEV, (P=O.O4 and P<O.OOOl, respectively). Stepwise logistic regression 
analysis showed that the number of positive prick results (OR= 1.15, 95% CI l.Ol-1.31) blood eosinophils (1.004, 
l.OO-l.Ol), level of FEV, (0.56, 0.36-0.87) and current smoking (2.36, 1.00-5.59) were factors significantly 
associated with the probability of hyper-responsiveness. Age, gender, atopy, pets and a history of ex-smoking were 
not significantly associated with hyper-responsiveness, neither in univariate nor in multivariate analyses. 
The Bayesian analysis was used to investigate the diagnostic value of the rapid methacholine challenge test. 
A receiver operator characteristic curve demonstrated that PD,,FEV, separated asthmatic and non-asthmatic 
patients better than PD,,FEV,. The best cutoff value of PD,,FEV, was 6OOOpg, but the difference from 
6900 pg was minimal, The best results of the test using a PD,,FEV, cutoff point of 6900 pug (PPV: 0.80, NPV: 0.79) 
were obtained when the pre-test probability was 0.48. The interval security of the test was established by a 
pre-test probability between 0.19 and 0.78. Maximal positive (0.34) and negative (0.31) final gains were achieved 
when pre-test probabilities were 0.33 and 0.65, respectively. The cutoff level of 150,~g gave 100% of specificity and 
predictive value of a positive test for clinical asthma diagnosis. The Bayesian analysis approach demonstrated 
that the test is useful in asthma diagnostics if not performed on patients with lowest or highest probabilities of 
asthma. 
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Received 1 July 1996 and accepted in revised form 18 December 
1996. 
Correspondence should be addressed to: J. Hedman, Department 
of Pulmonary Diseases, PBijZt-HBme Central Hospital, Keskus- 
sairaalankatu 7; FIN-15850 Lahti, Finland. 
Histamine or methacholine challenges are used both as a 
part of asthma diagnostics in clinical practice and in the 
follow-up of the efficacy of the treatment (l-6). Most 
asthma patients exhibit bronchial hyper-responsiveness in 
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TABLE 1. Anthropometric, blood eosinophils, skin prick test and lung function data on 230 patients 
tested for PD,,FEV, 
BHR positive BHR negative 
(n=78) (n= 152) 
Sex, (M/F) 
Age (years) 
Height (cm) 
Eosinophil count in peripheral blood (%) 
150 cells mm - 3 
15 l-400 cells mm ~ 3 
>400 cells mm - 3 
Skin prick 
Number of positive (2 3 mm) (%) 
0 positive 
1 positive 
2 positive 
3 positive 
FEV, (1) 
FEV, pred (%)t 
FVC (1) 
FVC pred (%)f 
28/50 62190 
44.0 (16.0)” 44.6 (16.2) 
167.6 (8.8) 167.9 (9.3) 
28 59 
47 35 
25 7 
41 54 
9 11 
7 7 
38 27 
2.98 (0.91) 3.23 (0.90) 
85.5 (14.8) 93.5 (13.9) 
3.94 (1.13) 4.00 (1.06) 
94.8 (15.0) 96.4 (12.8) 
*Mean (SD). tviljanen et al (8). BHR, bronchial hyper-responsiveness, threshold value: PD,,FEV, 
I 6900 ,ug. 
the methacholine test, but approximately 10% of asthmatic 
patients test negative when conventional methacholine 
doses up to 26OOpg are used (3). Larger cumulative 
methacholine doses might thus be used when studying the 
less hyper-responsive end of the unimodal distribution 
of bronchial hyper-responsiveness to methacholine in 
asthmatic patients. 
The primary aim of the study was to validate the rapid 
dosimetric methacholine challenge test (7) in asthma 
diagnostics. Secondary aims were to assess the distribution 
of bronchial hyper-responsiveness in a clinical material of 
patients with dyspnoea, wheezing or a cough of unknown 
cause, the genetic and environmental factors affecting 
hyper-responsiveness, and to compare the correlation 
between PD,,FEVr and PD,,FEV,. 
Methods 
SUBJECTS 
The study consisted of 230 consecutive adult patients tested 
with the rapid methacholine challenge at the Pulmonary 
Department of Lahti Central Hospital from May to 
September of 1994. The patients were referred to the clinic 
due to dyspnoea, wheezing or a cough of unknown cause. 
Patients with previous asthma diagnoses as well as those 
who had used inhaled steroids during the preceding 4 weeks 
were excluded. Anthropometric, eosinophil count in 
peripheral blood, skin prick test and lung function data are 
shown in Table 1. There were no differences in gender, age 
and height between methacholine positive and -negative 
groups, or between asthmatics and non-asthmatics. A & 
agonist was used by 58% of methacholine-positive and 32% 
of methacholine-negative patients (P<O.OOl), representing 
63% of the asthmatic and 33% of non-asthmatic patients, 
respectively (P<O.OOl). An anticholinergic drug was used 
by 5% of methacholine positive and 21% of methacholine 
negative patients (P<O.Ol), or 5% of asthmatics and 20% of 
non-asthmatics (WO.01). 
The study was approved by the Ethics Committee of 
Paijat-Hame Central Hospital. 
MEASUREMENTS 
A bell spirometer with a water seal (Could 2400°, 
SencorMedics Corporation, Yorba Linda, CA, U.S.A.) 
was used for lung function studies. The definitions and 
methods for performing lung volumes followed the 
recommendations of the European Coal and Steel 
Community (9). Each patient performed a minimum of 
three blows, and the greatest of three technically satisfac- 
tory forced vital capacities (FVC) and of the first three 
technically acceptable forced expiratory volumes in one 
second (FEV,) were reported. The chosen value did not 
exceed the next highest one by more than 5% or 0.1 1, 
whichever was greater. Measurements of volumes and 
ventilatory flows were corrected to BTPS (body tem- 
perature, pressure, saturated with water vapour). Skin 
prick tests were performed with a panel of 12 common 
allergens (pets, pollen and moulds) and with a negative and 
a positive control (Soluprick@!), ALK A/S, Copenhagen, 
Denmark). 
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TABLE 2. Smoking history of 230 patients tested for 
PD,,FEV, 
BHR BHR 
positive negative 
(n=78) (n=152) 
Never smoked (%) 
Ex-smoker (%) 
Current smoker (%) 
No. of cigarettes day ~ i (SD)* 
Pack (sD)~ years 
50 59 
27 25 
23 16 
14.7 (6.7) 13.8 (9.9) 
5.0 (8.7) 5.1 (9.9) 
*Smoked by current smokers. TMeans (SD) of entire groups. 
BHR, bronchial hyper-responsiveness, threshold value: 
PD,,FEVi 2 6900 pg. 
Details of a patient’s respiratory symptom history were 
collected by a questionnaire dealing with respiratory symp- 
toms (dyspnoea, wheezing, cough, phlegm production), 
disposition to atopic diseases, asthma or atopy in first- 
degree relatives, pets, and previous and actual treatment 
(including the use of asthma medication). The patients’ 
smoking histories were also noted and are given in Table 2. 
DIAGNOSIS OF ASTHMA 
The measurement of bronchial responsiveness was not used 
as a diagnostic criterion for asthma. Asthma diagnosis 
was based on a clinical evaluation by the attending chest 
physicians. The guidelines of the American Thoracic 
Society (ATS) for the diagnosis of bronchial asthma (10) 
were used. The fulfillment of diagnostic criteria was 
checked in the analysis phase, and the person who classified 
the patients as asthmatics or non-asthmatics was blinded to 
PD,,FEV,. Patients had to have a documented variation in 
FEV, or PEF (peak expiratory flow) of 15% or greater after 
medication, or repeatedly a 20% or greater spontaneous 
daily variation in PEF monitoring during a period of 
2 weeks. In addition, a 15% or greater decrease in FEV, 
after a specific allergen provocation or during an exercise 
test was a criterion for diagnosing bronchial asthma. 
Patients were instructed to perform three measurements of 
PEF with a mini-Wright peak flow meter every morning 
and evening. The best value was recorded in the patient’s 
diary. Patients were regarded as intrinsic asthmatics if they 
had no evidence of extrinsic asthma from history or in 
results from skin tests. The remaining patients were defined 
as having extrinsic asthma (11). 
METHACHOLINE BRONCHIAL CHALLENGE 
The rapid dosimetric methacholine challenge test, 
performed with a pocket turbine spirometer (Micro 
SpirometerQ Micro Medical Instruments Ltd, Rochester, 
U.K.), was used and the volume calibration of the pocket 
spirometer was checked with calibration pumps as 
described previously (7). Turbine volume transducers are 
preselected by the manufacturer to provide volume readings 
with an accuracy of f 2% and cannot be calibrated by 
the user. Volume calibration was checked daily, using 
a 2000ml (JaegerO, Erich Jaeger GmbH, Wiizburg, 
Germany) calibration pump. An automatic, inhalation 
synchronized dosimeter jet nebulizer, the Spira Elektro 2 
(Respiratory Care Center, Hameenlinna, Finland) was used 
for methacholine delivery (12). Patients had to have a FEV, 
of at least 65% of predicted before the challenge, and were 
not allowed to have any respiratory infection during the 
previous 4 weeks. Prior to the challenges, patients were not 
allowed to use /&-sympathomimetic drugs for 12 h, nor any 
other asthma or antihistaminic drugs for 48 h (terfenadine 
for 1 week and astemitsole for 4 weeks). Moreover, patients 
were not allowed to drink tea, coffee or cola drinks for 4 h 
before the test. After nebulization of 33 g isotonic saline (4), 
methacholine chloride was delivered in four cumulative 
doses of 80, 400, 1700 and 69OObg. As the pH of metha- 
choline solutions is stable, no buffering was needed (5). The 
concentrations of methacholine were 2.5, 10, 40 and 
160mgml-‘. For the baseline, FEV, was recorded from at 
least three successive determinations after the inhalation of 
33 g saline. Ninety seconds after each methacholine dose, 
three successive determinations of FEV, were made. If 
FEV, decreased from the baseline by 20% or more after any 
dose, further administration of methacholine was discontin- 
ued. After the last methacholine dose, patients were given 
2OOpg of salbutamol aerosol to resolve bronchoconstric- 
tion. The fall in FEV, was plotted against methacholine 
dose on a log scale, and the provocative dose causing a 20% 
fall in FEV, PD,,FEVi was estimated by interpolation 
from the dose-response curve. PDi,FEV, was calculated 
from the same provocations. 
STATISTICAL METHODS 
The Chi-square or Fischers exact tests were used to test 
differences between proportions, and Students t-test was 
used to compare the group means. The Mann-Whitney 
t-test was used to compare the groups with respect to the 
level of bronchial responsiveness, where an arbitrary 
PD,,FEV, value of 27 38Opg was given to non-responders 
(PD,,FEV, >6900 pug). Stepwise logistic regression analysis 
was performed to investigate the association of age, 
gender, smoking, number of positive prick results, blood 
eosinophils, lung function, pets and history of atopy and 
asthma in relatives, with responsiveness as a dichotomous 
variable. Methacholine-positive patients (PD,,FEV, 
I 6900 pug) were defined as hyper-responsive. 
Sensitivity (Se), specificity (Sp) and the predictive values 
of a positive test (PV+) and of a negative test (PV - ) for 
the diagnosis of asthma from the rapid methacholine 
challenge test - based on the distribution of PD,,FEV, 
and PD,,FEV, in the clinical material-were calculated 
according to the following formulas: 
Se(%) = 
true positives 
x 100 
true positives + false negatives 
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sp (%)= 
true negatives 
x 100 
true negatives + false positives 
PV + (%) = 
true positives 
x 100 
true positives+false positives 
PV - (%) = 
true negatives 
x 100 
true negatives+false negatives 
To compare PD,,FEV, and PD,,FEV, -as well as to 
detect the best cutoff point in separating asthmatic and 
non-asthmatic patients ~ receiver operator characteristic 
curves were graphically constructed by plotting sensitivity 
against the false-positive rate (1 - specificity) for several 
cutoff point values. The predictive values are strongly 
influenced by the prevalence of the disease. With the best 
cutoff value, the post-test probabilities both of asthma after 
a positive (PPV) or negative (I-NPV) provocation test 
result and of non-asthma after a NPV for all possible 
pre-test probabilities were determined according to Bayes’ 
theorem: 
PPV (positive predictive value) = 
Pr X Se 
(Pr X Se)+(l - Pr) x (1 - Sp) 
NPV (negative predictive value) = 
(1 - Pr) x Sp 
(1 - Pr) X Sp+Pr X (1 -Se) 
where Pr is the prior probability of the disease. The 
difference between PPV or l-NPV and the pre-test 
probability is the positive or negative diagnostic gain of the 
test. The PPV and l-NPV for several cutoff points of the 
methacholine were also calculated (14). 
Results 
The rapid methacholine challenge test was performed with 
230 consecutive patients who had dyspnoea, wheezing or a 
prolonged cough of unknown cause. Seventy-eight patients 
(34%) were methacholine positive (PD,,FEV, I 6900 ,ug), 
47 (60%) of whom had a final diagnosis of ATS criteria 
fulfilling bronchial asthma. The geometric mean provoca- 
tive dose in methacholine positive patients was 2013 pg 
(SD 2OlO~g). One hundred and fifty-two patients (66%) 
were methacholine negative (PD,,FEV, >6900 pug), 14 (9%) 
of whom had bronchial asthma according to clinical 
evaluation. Increased bronchial responsiveness was 
strongly associated with the ATS criteria fulfilling asthma 
k2=68.92, P<O.OOOl). 
The material was consequently divided into two groups 
of 61 (27%) asthmatic and 169 (73%) non-asthmatic 
patients. The distribution of PD,,FEV, values in patients 
with and without asthma is shown in Fig. 1. When 
PD,,FEV, was used, 47 (77%) of the asthmatic were 
hyper-responsive (range 40-69OOpg) as were 31 (18%) of 
100 000 
14. 
11 I I 
Non-asthmatics Asthmatics 
(n = 169) (n = 61) 
FIG. 1. Distribution of PD,,FEV, values in 61 patients 
with and 169 patients without asthma. An arbitrary 
PD,,FEV, value of 27 380,~~g was given to 152 non- 
responders in methacholine challenge (PD,,FEV, 
>6900 pug). 
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FIG. 2. Distribution of PD,,FEV, in 78 hyper-responsive 
(47 asthmatic and 31 non-asthmatic) patients (PD,,FEV, 
<69OOpg). Open bars, asthmatic; solid bars, non- 
asthmatic. 
the non-asthmatics (range 160-6900 pug). The distribution 
of PD,,FEV, in 78 hyper-responsive patients is shown in 
Fig. 2. When using PD,,FEV,, 51 (84%) of the asthmatic 
patients (range 28-69OOpg) and 52 (31%) of the non- 
asthmatic patients (range 100-6900 pug) were hyper- 
responsive. The level of bronchial responsiveness measured 
by both PD,,FEV, and PD,,FEV, differed significantly 
between asthmatics and non-asthmatics (P~O.0001). 
The data of sensitivity, specificity and predictive value of 
positive and negative test for the diagnosis of asthma from 
the methacholine challenge test - based on the distribution 
of PD,,FEV, and PD,,FEV, - are shown in Table 3. The 
receiver operator characteristic curves of PD,,FEV, and 
PD,,FEV, for distinguishing asthmatic from non- 
asthmatic patients is shown in Fig. 3. As can be graphically 
observed, PD,,FEV, is more discriminating than 
PD,,FEVi, and the best PD,,FEV, cutoff point is 6OOOpg 
(sensitivity and specificity: 0.75 and 0.85, respectively); the 
difference from 6900,~~g is, however, minimal (sensitivity 
and specificity: 0.77 and 0.82, respectively). Taking this into 
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TABLE 3. Sensitivity (Se), specificity (Sp), predictive value of 
positive test (PV+) and predictive value of negative test 
(PV - ) for diagnosis of asthma of the rapid methacholine 
challenge test based on PD,,FEV, and PD,,FEV, in 230 
patients with dyspnoea, wheezing or prolonged cough 
(threshold value I 6900 ,ug) 
(E) 
pv+ 
W> 
PV- 
(%I 
PD,,FEV, 
PD,,FEVr 
(74:3)* (6276) (4f?59) (87%7) 
(677-788) (76:7) (496-071) (8:95) 
*95% confidence interval. 
Y I I I I I I I I I 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
False-positive rate 
FIG. 3. Receiver operator characteristic curve for different 
cutoff values of PD,,FEVr (0) and PD,,FEVr (e). 
account, the post-test probability of asthma or non-asthma 
with all the pre-test probabilities was determined using a 
PD,,FEV, cutoff point of 6900 pg (Fig. 4). The best results 
(PPV: 0.80, NPV: 0.79) were obtained when the pre-test 
probability was 0.48. The interval security of the test (i.e. 
the pre-test probability range when PPV and NPV were 
greater than 50%) was established with a pre-test 
probability between 0.19 and 0.78. The maximal positive 
(0.34) and negative (0.31) final gains were achieved when 
pre-test probabilities were 0.33 and 0.65, respectively 
(Fig. 5). The curves of PPV and l-NPV, using several 
PD,,FEV, cutoff points, were also determined (Fig. 6). 
The mean daily variation in PEF was significantly higher 
in hyper- responsive patients than in non-hyper-responsives 
(18 vs lo%, ) P<O.OOOl). Likewise, there was a signifi- 
cant difference in the number of blood eosinophils be- 
tween hyper-responsive and non-hyper-responsive patients 
i 0 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
Pre-test probability 
FIG. 4. Curves for post-test probability of asthma after a 
positive provocation test result (PPV, 0) and post-test 
probability of non-asthma after a negative provocation 
test result (NPV, 0) using a cutoff value for PD,,FEVr of 
6900 ,ug. 
, 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
Pre-test probability 
FIG. 5. Post-test probability of asthma after a PPV (0) or 
I-NPV (B) test. G (+), maximal positive ‘diagnostic gain 
of the test; G ( - ), maximal negative diagnostic gain of 
the test. 
(Table 1) (306 vs 185 cells mm ~ 3, P<O.OOOl; distribution 
x*=23.90, P<O.OOOOl). Hyper-responsive patients had sig- 
nificantly lower levels of FEV, and percentage of predicted 
FEV, than non-hyper-responsives (2.98 vs 3.23 1 min - r, 
p=O.O4; 86 vs 94%, P<O.OOOl, respectively). There was no 
association with hyper-responsiveness in FVC and percent- 
age of predicted FVC, nor in respect to age, gender, atopy, 
history of asthma or atopy in close relatives and pets. There 
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FIG. 6. Curves for post-test probability of asthma after PPV or l-NPV test using different cutoff values of PD,,FEV,. 
TABLE 4. Results of logistic regression analysis 
Conclusions 
Odds Ratio* 95% CI 
Skin prick (# positive) 1.15 l.OlL1.31 
Blood eosinophils 1,004 1~00~1~01 
FEV, 0.56 0.36-0.87 
Ex-smoking 1.72 0.7993.76 
Current smoking 2.36 1.00-5.59 
*Change in odds ratio after one unit change in skin prick, 
blood eosinophils and FEV,. 
Hyper-responsiveness (dichotomous variable using a 
PD,,FEV, threshold value of 69OOpg) is explained with 
number of positive prick results, blood eosinophils, FEV, 
(1) and smoking (never-smokers as a reference group). 
were no significant differences between the groups 
regarding smoking history (Table 2). Hyper-responsiveness 
was not significantly more common in the univariate 
analysis among smoking patients than among non-smokers 
(43 vs 32%, p=O. 18), nor was the difference in levels of 
hyper-responsiveness significant (P= 0.14). 
The results of regression analysis are given in Table 4. 
Hyper-responsiveness was considered a dichotomous vari- 
able using a PDZOFEV, threshold value of 6900,~g. A 
greater number of positive prick results (OR= 1.15, 95% 
CI l.Ol-1.31), and blood eosinophils (OR=1,004, 95% CI 
l.OO-1.01) a lower level of FEV, (OR=0.56, 95% CI 
0.36-0.87) and current smoking (ORz2.36, 95% CI l.OO- 
5.59) were factors significantly associated with an increased 
probability of hyper-responsiveness. A history of ex- 
smoking, age, gender, pets and a history of atopy or asthma 
in relatives were not significantly associated with hyper- 
responsiveness. 
To the authors’ knowledge, this was the first clinical study 
to assess the use of such a high dose methacholine challenge 
in the evaluation of patients with dyspnoea, wheezing or a 
cough of unknown cause. A main task of the clinician- 
bearing in mind the favourable outcomes possible through 
early intervention including allergen avoidance and anti- 
inflammatory therapy-is to diagnose the possibility of 
even mild forms of asthma. A crucial question looms: can a 
cutoff dose of inhaled methacholine be determined which, 
as a standalone test, could ensure asthma diagnosis for 
clinical decision making or for epidemiological purposes? 
The present rapid method, with its high negative predictive 
value of 91%, appears at least as efficient as previous 
dosimetric methacholine tests for excluding chronic asthma 
(3). The present authors have been able to demonstrate 
that a cutoff level of 15Opg provides 100% of specificity 
and predictive value of a positive test for clinical asthma 
diagnosis. 
The geometric mean for PD,,FEV, was 146Opg in 
hyper-responsive asthmatic patients, while in the preceding 
methacholine test, the geometric mean for corresponding 
patients was 255 pug (3). However, two to three times higher 
total doses of methacholine were given in the present 
method compared to previous conventional dosimeter 
methods. The shorter protocol seems to yield higher PD,, 
values than those obtained from the previous protocol, as 
expected by Kennedy and Contreras (13). Part of the 
difference is, however, influenced by the inclusion criteria of 
the present study: all patients with a former asthma diag- 
nosis and/or who had used inhaled steroids during the 
previous 4 weeks were excluded. The sensitivity of the test is 
related to the characteristics of asthmatic patients and their 
current status of asthma symptoms (14). The inclusion 
criteria of this study, as well as the referral pattern of 
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general practitioners (15) can thus affect the sensitivity of 
the test. The Bayesian analysis approach showed that the 
present rapid methacholine challenge is as capable as 
previous methods in distinguishing between normal and 
asthmatic subjects (14,16). A receiver-operator curve was 
used to detect the best cutoff point of PD,,FEV, and 
PDrSFEV, to separate asthmatic from non-asthmatic sub- 
jects. PD,,FEV, proved more discriminating; the best 
PD,,FEV, cutoff point was 6000 pug (sensitivity and specifi- 
city: 0.75 and 0.85, respectively). The difference from 
69OOpg was minimal (sensitivity and specificity: 0.77 and 
0.82, respectively), and further statistics were gathered 
based on 69OOpg. This can also be argued by the slightly 
improved ability of the test to determine asthmatics (sensi- 
tivity was improved). The best results of the test were 
obtained when the pre-test probability was 0.48 -exactly 
the result of Perpina et al. (14). The diagnostic content of 
the test is maximal when the prior probability of asthma is 
between 0.33 (maximal positive final gain 0.34) and 0.65 
(maximal negative final gain 0.31). Based on the interval 
security, the rapid test could only be considered if prior 
probability is established between 0.19 and 0.78. The 
methacholine test is useful if not performed on patients with 
the lowest or highest probabilities of asthma (14). By 
referring to Fig. 6, the probability of asthma after a positive 
and negative test can be established after determining the 
individual PD,,FEV, and the clinical estimate of asthma. 
In clinical practice, however, it is quite difficult to estimate 
the exact pre-test probability of asthma, which should be 
based on the history, physical examination and laboratory 
data. Universally accepted criteria for different pre-test 
probabilities are needed. The curves for different cutoff 
values must also be constructed when comparing different 
studies (14). 
Genetic and environmental factors influencing hyper- 
responsiveness of the airways to methacholine were also 
evaluated. Bronchial hyper-responsiveness was associated 
with asthma, daily variation of PEF, blood eosinophils and 
inversely with the level of FEV, and percentage of predicted 
FEV,. However, no association was found with prick test 
positivity, atopy and history of atopy or asthma in relatives. 
The association of excessive PEF variability and bronchial 
hyper-responsiveness to methacholine has been shown pre- 
viously in a population sample (17). The infiltration of 
inflammatory cells in the lamina propria of the airways of 
the asthmatic patients is, however, inversely related to PC,, 
for methacholine but not to symptoms and lung function, 
including PEF variability (6). This finding also emphasizes 
the importance of the methacholine test in the follow-up of 
asthmatic patients. Atopy has been shown to be a major 
determinant for asthma in children (18). Postma et al. (19) 
demonstrated that a trait for elevated levels of serum 
total IgE is coinherited with a trait for bronchial hyper- 
responsiveness, and that a gene governing bronchial hyper- 
responsiveness is located near a major locus that regulates 
serum IgE levels in chromosome 5 q. Bronchial responsive- 
ness was not, however, correlated with serum total IgE 
levels. These results also support the hypothesis that hyper- 
responsiveness genes differ from those controlling atopy 
and asthma. 
Bronchial hyper-responsiveness was unimodally distri- 
buted in the asthmatic patients, which is in accordance with 
previous results (3,20,21). The absolute blood eosinophil 
count is associated with hyper-responsiveness. A difference 
was also found between asthmatic and non-asthmatic 
patients concerning inflammatory activity in the respiratory 
tract. This finding is also in accordance with previous 
results (11,22,23). The history of current smoking but not of 
ex-smoking was found in regression analysis to associate 
with the occurrence of hyper-responsiveness. Over one- 
third of the patients had pets but this had no association 
with hyper-responsiveness. The more frequent use of 
P,-agonists by hyper-responsive and asthmatic patients 
reflects the pre-test probability of asthma in patients with 
dyspnoea, wheezing or a cough of unknown cause. 
Although the cumulative methacholine dose was rather 
high in the present rapid challenge, 9% of the patients who 
showed no hyper-responsiveness to methacholine had 
bronchial asthma according to clinical evaluation. It is 
possible that even higher cumulative doses - especially 
with rapid methods -could be used when studying the 
less hyper-responsive end of the unimodal distribution 
of bronchial hyper-responsiveness to methacholine in 
asthmatic patients. This study shows that the test is useful 
in asthma diagnostics if not performed on patients with 
lowest or highest probabilities of asthma. The authors were 
also able to demonstrate that a cutoff level of 15Opg gives 
100% of specificity and predictive value of a positive test for 
clinical asthma diagnosis. 
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